Body Mass Index Influence on the Clinical Outcomes for Nonvalvular Atrial Fibrillation Patients Admitted to a Hospital Treated with Direct Oral Anticoagulants: A Retrospective Cohort Study

References

• KirchhofP, BenussiS, KotechaD, et al.; ESC Scientific Document Group. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–2962.27567408
   PubMed Web of Science ®Google Scholar
• JanuaryCT, WannLS, CalkinsH, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College Of Cardiology/American Heart Association task force on clinical practice guidelines and the heart rhythm society in collaboration with the Society Of Thoracic Surgeons. Circulation. 2019;140(2):e125–e151. doi:10.1161/CIR.000000000000066530686041
   PubMed Web of Science ®Google Scholar
• MooreKT, KröllD. Influences of Obesity and bariatric surgery on the clinical and pharmacologic profile of rivaroxaban. Am J Med. 2017;130(9):1024–1032. doi:10.1016/j.amjmed.2017.05.01128601546
   PubMed Web of Science ®Google Scholar
• ReillyPA, LehrT, HaertterS, et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol. 2014;63(4):321–328. doi:10.1016/j.jacc.2013.07.10424076487
   PubMed Web of Science ®Google Scholar
• BreuerL, RingwaldJ, SchwabS, KöhrmannM. Ischemic stroke in an obese patient receiving dabigatran. N Engl J Med. 2013;368(25):2440–2442. doi:10.1056/NEJMc1215900
   PubMed Web of Science ®Google Scholar
• LucijanicM, JurinI, JurinH, et al. Patients with higher body mass index treated with In review direct/novel oral anticoagulants (DOAC/DOAC) for atrial fibrillation experience worse clinical outcomes. Int J Cardiol. 2020;301:90–95. doi:10.1016/j.ijcard.2019.10.03531748190
   PubMed Web of Science ®Google Scholar
• SafourisA, DemulderA, TriantafyllouN, TsivgoulisG. Rivaroxaban presents a better pharmacokinetic profile than dabigatran in an obese non-diabetic stroke patient. J Neurol Sci. 2014;346(1–2):366–367. doi:10.1016/j.jns.2014.09.00825240443
   PubMed Web of Science ®Google Scholar
• SandhuRK, EzekowitzJ, AnderssonU, et al. The ‘obesity paradox’ in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial. Eur Heart J. 2016;37(38):2869–2878. doi:10.1093/eurheartj/ehw12427071819
   PubMed Web of Science ®Google Scholar
• Di NisioM, VedovatiMC, Riera-MestreA, et al. Treatment of venous thromboembolism with rivaroxaban in relation to body weight. A sub-analysis of the EINSTEIN DVT/PE studies. Thromb Haemost. 2016;116(4):739–746. doi:10.1160/TH16-02-008727535349
   PubMed Web of Science ®Google Scholar
• GülerE, Babur gülerG, DemirGG, HatipoğluS. A review of the fixed dose use of new oral anticoagulants in obese patients: is it really enough? Anatol J Cardiol. 2015;15(12):1020–1029. doi:10.5152/AnatolJCardiol.2015.653226663225
   PubMed Web of Science ®Google Scholar
• World Health Organisation. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000;894:i–253.11234459
   PubMed Web of Science ®Google Scholar
• GuyattGH, NorrisSL, SchulmanS, et al. Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2):53S–70S. doi:10.1378/chest.11-228822315256
   PubMed Web of Science ®Google Scholar
• SpyropoulosAC, BrohiK, CapriniJ, et al.; SSC Subcommittee on Perioperative and Critical Care Thrombosis and Haemostasis of the International Society on Thrombosis and Haemostasis. Scientific and Standardization Committee Communication: guidance document on the periprocedural management of patients on chronic oral anticoagulant therapy: recommendations for standardized reporting of procedural/surgical bleed risk and patient-specific thromboembolic risk. J Thromb Haemost. 2019;17 (11):1966–1972.31436045
   PubMed Web of Science ®Google Scholar
• YaoX, AbrahamNS, AlexanderGC, et al. Effect of adherence to oral anticoagulants on risk of stroke and major bleeding among patients with atrial fibrillation. J Am Heart Assoc. 2016;5(2):e003074. doi:10.1161/JAHA.115.00307426908412
   PubMed Web of Science ®Google Scholar
• EikelboomJW, QuinlanDJ, HirshJ, ConnollySJ, WeitzJI. Laboratory monitoring of non-vitamin k antagonist oral anticoagulant use in patients with atrial fibrillation: a Review. JAMA cardiol. 2017;2(5):566–574. doi:10.1001/jamacardio.2017.036428355459
   PubMed Web of Science ®Google Scholar
• UprichardJ. Management of rivaroxaban in relation to bodyweight and body mass index. Ther Adv Cardiovasc Dis. 2016;10(5):294–303. doi:10.1177/175394471664364527090286
   PubMedGoogle Scholar
• NetleyJ, HowardK, WilsonW. Effects of body mass index on the safety and effectiveness of direct oral anticoagulants: a retrospective review. J Thromb Thrombolysis. 2019;48(3):359–365. doi:10.1007/s11239-019-01857-230963393
   PubMed Web of Science ®Google Scholar
• MurakawaY, IkedaT, OgawaS, et al. Impact of body mass index on real-world outcomes of rivaroxaban treatment in Japanese patients with non-valvular atrial fibrillation. Heart Vessels. 2020;35(8):1125–1134. doi:10.1007/s00380-020-01587-z32253531
   PubMed Web of Science ®Google Scholar
• TittlL, EndigS, MartenS, ReitterA, Beyer-WestendorfI, Beyer-WestendorfJ. Impact of BMI on clinical outcomes of DOAC therapy in daily care—results of the prospective Dresden DOAC Registry (NCT01588119). Int J Cardiol. 2018;262:85–91. doi:10.1016/j.ijcard.2018.03.06029622509
   PubMed Web of Science ®Google Scholar
• Echouffo-TcheuguiJB, XuH, MatsouakaRA, et al. Diabetes and long-term outcomes of ischaemic stroke: findings from get with the guidelines-stroke. Eur Heart J. 2018;39(25):2376–2386. doi:10.1093/eurheartj/ehy03629438515
   PubMed Web of Science ®Google Scholar
• SchulmanS, KearonC, KakkarAK, et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013;368(8):709–718. doi:10.1056/NEJMoa111369723425163
   PubMed Web of Science ®Google Scholar
• KidoK, NgorsurachesS. Comparing the efficacy and safety of direct oral anticoagulants with warfarin in the morbidly obese population with atrial fibrillation. Ann Pharmacother. 2019;53(2):165–170. doi:10.1177/106002801879660430130979
   PubMed Web of Science ®Google Scholar
• PiranS, TraquairH, ChanN, BhagirathV, SchulmanS. Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120 kilograms: a retrospective study. Res Pract Thromb Haemost. 2018;2(4):684–688. doi:10.1002/rth2.1214630349887
   PubMed Web of Science ®Google Scholar
• Di MinnoMN, LupoliR, Di MinnoA, AmbrosinoP, ScaleraA, DentaliF. Effect of body weight on efficacy and safety of direct oral anticoagulants in the treatment of patients with acute venous thromboembolism: a meta-analysis of randomized controlled trials. Ann Med. 2015;47(1):61–68. doi:10.3109/07853890.2014.98206425665582
   PubMed Web of Science ®Google Scholar
• LeeCH, LinTY, ChangSH, et al. Body mass index is an independent predictor of major bleeding in non-valvular atrial fibrillation patients taking dabigatran. Int J Cardiol. 2017;228:771–778. doi:10.1016/j.ijcard.2016.11.27727888754
   PubMed Web of Science ®Google Scholar
• KoscielnyJ, RosenthalC, von HeymannC. Update on direct oral anticoagulants (DOACs). update direkte orale antikoagulanzien (DOAKs)—perioperatives “Switching”, Medikamenteninteraktionen und Persistenz. Hamostaseologie. 2017;37(4):267–275. doi:10.5482/HAMO-16-10-004129582929
   PubMed Web of Science ®Google Scholar
• KubitzaD, BeckaM, ZuehlsdorfM, MueckW. Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J Clin Pharmacol. 2007;47(2):218–226. doi:10.1177/009127000629605817244773
   PubMed Web of Science ®Google Scholar
• KidoK, LeeJC, HellwigT, GulsethMP. Use of direct oral anticoagulants in morbidly obese patients. Pharmacotherapy. 2020;40(1):72–83. doi:10.1002/phar.235331834939
   PubMed Web of Science ®Google Scholar
• MartinAC, ThomasW, MahirZ, et al. Direct oral anticoagulant concentrations in obese and high body weight patients: a Cohort Study. Thromb Haemost. 2020.
   Google Scholar
• YamashitaT, KoretsuneY, YasakaM, et al. Randomized, multicenter, warfarin-controlled Phase II study of edoxaban in Japanese patients with non-valvular atrial fibrillation. Circ J. 2012;76(8):1840–1847. doi:10.1253/circj.CJ-11-114022664798
   PubMed Web of Science ®Google Scholar
• CovertK, BranamDL. Direct-acting oral anticoagulant use at extremes of body weight: literature review and recommendations. Am J Health Syst Pharm. 2020;77(11):865–876. doi:10.1093/ajhp/zxaa05932426845
   PubMed Web of Science ®Google Scholar
• BoonyawatK, CaronF, LiA, et al. Association of body weight with efficacy and safety outcomes in Phase III RANDOMIZED controlled trials of direct oral anticoagulants: a systematic review and meta-analysis. J Thromb Haemost. 2017;15(7):1322–1333. doi:10.1111/jth.1370128407368
   PubMed Web of Science ®Google Scholar
• KvasnickaT, MalikovaI, ZenahlikovaZ, et al. Rivaroxaban - Metabolism, pharmacologic properties and drug interactions. Curr Drug Metab. 2017;18(7):636–642. doi:10.2174/138920021866617051816544328524005
   PubMed Web of Science ®Google Scholar
• HijaziZ, OldgrenJ, LindbäckJ, et al. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet. 2016;387(10035):2302–2311. doi:10.1016/S0140-6736(16)00741-827056738
   PubMed Web of Science ®Google Scholar
• Di FuscoSA, LucàF, BenvenutoM, et al. Major bleeding with old and novel oral anticoagulants: how to manage it. Focus on general measures. Int J Cardiol. 2018;387:80–84. doi:10.1016/j.ijcard.2018.05.061
   Web of Science ®Google Scholar
• BaberU, MastorisI, MehranR. Balancing ischaemia and bleeding risks with novel oral anticoagulants. Nat Rev Cardiol. 2014;11(12):693–703. doi:10.1038/nrcardio.2014.17025367652
   PubMed Web of Science ®Google Scholar
• KaplanRM, TanakaY, PassmanRS, et al. Efficacy and safety of direct oral anticoagulants for atrial fibrillation across body mass index categories. J Am Heart Assoc. 2020;9(24):e017383. doi:10.1161/JAHA.120.01738333302751
   PubMed Web of Science ®Google Scholar
• AlmaLJ, De GrootC, De MenezesRX, HermesW, HordijkPL, KovačevićI. Endothelial dysfunction as a long-term effect of late onset hypertensive pregnancy disorders: high BMI is key. Eur J Obstet Gynecol Reprod Biol. 2018;225:62–69. doi:10.1016/j.ejogrb.2018.04.00329677687
   PubMed Web of Science ®Google Scholar
• Farpour-LambertNJ, MartinXE, SBDT, et al. Effectiveness of individual and group programmes to treat obesity and reduce cardiovascular disease risk factors in pre-pubertal children. Clin Obes. 2019;9(6):e12335. doi:10.1111/cob.1233531415133
   PubMed Web of Science ®Google Scholar